FATE Fate Therapeutics Inc
Market Cap
618.98M
Day’s Range
52W Range
Volume (3M)
3.36M
Price-Earnings Ratio
-
Revenue
69.01M
Fate Therapeutics Inc Latest News
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Fate Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 22, 2023 - (NASDAQ: FATE)PR Newswirea day agoDEADLINE ALERT for BVS, GWH, YMAB, FATE: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of ShareholdersGlobeNewswire2 days ago
About Fate Therapeutics Inc
Fate Therapeutics is an American biopharmaceutical company founded in 2007 and based in San Diego, California. The organisation specialises in the development of programmed cellular immunotherapies for cancer and immune disorders. It serves healthcare professionals across the USA, manufacturing a range of therapies based on their iPSC-derived cell product candidates. Fate Therapeutics bases their cellular immunotherapies on their novel ex vivo cell programming approach.
The company started trading publicly on the NASDAQ GS in 2013, using the ticker FATE. In October 2020, the FATE price chart was showing a 52-week low of $12.59 and a 52-week high of $42.22, with a market cap of $3.3bn. The company does not expect to pay any cash or other dividend on its common stock.
This innovative and specialist healthcare company collaborates with numerous respected partners, including Janssen Biotech, ONO Pharmaceutical Co., and the Masonic Cancer Centre at the University of Minnesota. These collaborations have led to advancements in the first-ever iPSC-derived cell therapy — FT500 — and the first-ever engineered iPSC-derived cell therapy — FT516. This resulted in the clinical development of these therapies in the United States.
If you are interested in FATE stock, you can track this instrument by adding it to your eToro watchlist.
Show More449
Employees
San Diego, California, US
HQ
2007
Founded
J. Scott Wolchko
CEO
Upcoming Earnings
27
FEB
REPORTS
Fate Therapeutics Inc Q4 2022 earnings report is expected to be released after market open
Get insight into a company's sustainability using ESG (environmental, social, and governance) scores.
0
100
42
Very Low
Industry
Avg. 45
32
Environment
45
Social
47
Governance
People Also Bought
ARWR Arrowhead Pharmaceuticals Inc 0.98% 
NVCR Novocure Ltd 3.37% 
CERS Cerus Corp 2.63% 
RVNC Revance Therapeutics Inc 0.31% 
OSH Oak Street Health Inc. -3.39% 
ZLAB Zai Lab Limited-ADR 0.48% 
AUPH Aurinia Pharmaceuticals Inc. 1.36% 
NSTG NanoString Technologies Inc. 4.86%